You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
The guideline for clopidogrel and CYP2C19 for Poor Metabolizers, for cardiovascular indications (Table 2) recommends "Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication"
However, the database contains "Avoid standard dose (75 mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication."
It's a small difference, but the first one conveys a stronger contraindication. I understand that sombody has manually curated the published guidelines. I would be interested to know if this was a typo, or maybe there's a new guideline I'm not aware of.
Thanks
The text was updated successfully, but these errors were encountered:
Hi,
The guideline for clopidogrel and CYP2C19 for Poor Metabolizers, for cardiovascular indications (Table 2) recommends "Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication"
However, the database contains "Avoid standard dose (75 mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication."
It's a small difference, but the first one conveys a stronger contraindication. I understand that sombody has manually curated the published guidelines. I would be interested to know if this was a typo, or maybe there's a new guideline I'm not aware of.
Thanks
The text was updated successfully, but these errors were encountered: